Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amphotericin B

FDA-approved product (ointment, topical), marketed as Abelcet, Ambisome, Amphotec and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amphotericin B
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Cryptococcal meningitis
  • Cryptococcosis
  • Fungal infectious disease
  • Histoplasmosis
  • Infection
  • Mucormycosis
  • Sporotrichosis
  • Visceral Leishmaniasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antibiotics
FDA pharmacologic class
Lipid-based Polyene Antifungal; Polyene Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC A01AB04; WHO ATC A07AA07; WHO ATC G01AA03; WHO ATC J02AA01; FDA class Lipid-based Polyene Antifungal; FDA class Polyene Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 1 lab record
Open Amphotericin B in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amphotericin B with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Three Induction Treatments on Cryptococcal Meningitis

    NCT04072640 · start 2021-01-25

    Registered record
    Registry ID
    NCT04072640
    Conditions
    Cryptococcal Meningitis; HIV/AIDS
    Interventions
    Voriconazole 200mg; amphotericin B deoxycholate (0.4-0.5mg/kg/d); Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2021-01-25
    Completion
    2022-12-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptococcal Meningitis; HIV/AIDS
    InterventionVoriconazole 200mg; amphotericin B deoxycholate (0.4-0.5mg/kg/d); Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
    PhaseEarly phase 1
    Registry statusUnknown

  • Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis

    NCT04532463 · start 2020-10-01

    Registered record
    Registry ID
    NCT04532463
    Conditions
    Cryptococcal Meningitis
    Interventions
    Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-10-01
    Completion
    2022-04-20
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptococcal Meningitis
    InterventionAmphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics and Safety of AmBisome and DKF-5122

    NCT05749380 · start 2020-09-07

    Registered record
    Registry ID
    NCT05749380
    Conditions
    Invasive Fungal Infections; Neutropenic Fever
    Interventions
    AmBisome; DKF-5122
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-07
    Completion
    2022-01-28
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections; Neutropenic Fever
    InterventionAmBisome; DKF-5122
    PhasePhase 1
    Registry statusCompleted

  • Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis

    NCT04502381 · start 2020-07-01

    Registered record
    Registry ID
    NCT04502381
    Conditions
    Pulmonary Mucormycosis
    Interventions
    Inhaled amp B deoxycholate+intravenous liposomal amp B; Intravenous liposomal amphotericin B alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2021-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Mucormycosis
    InterventionInhaled amp B deoxycholate+intravenous liposomal amp B; Intravenous liposomal amphotericin B alone
    PhasePhase 2
    Registry statusCompleted

  • A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

    NCT04993222 · start 2020-06-04

    Registered record
    Registry ID
    NCT04993222
    Conditions
    Bioequivalence
    Interventions
    Amphotericin B liposome for injection; AmBisome®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-04
    Completion
    2020-11-16
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionAmphotericin B liposome for injection; AmBisome®
    PhasePhase 1
    Registry statusCompleted

  • Effect of Topical Sinonasal Antibiotics

    NCT03935828 · start 2019-06

    Registered record
    Registry ID
    NCT03935828
    Conditions
    Chronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    Interventions
    Oral versus topical antibioitics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2021-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    InterventionOral versus topical antibioitics
    PhasePhase 2
    Registry statusWithdrawn

  • Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China

    NCT03577509 · start 2018-07-02

    Registered record
    Registry ID
    NCT03577509
    Conditions
    Invasive Fungal Disease
    Interventions
    ABCD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-02
    Completion
    2018-09-14
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Disease
    InterventionABCD
    PhasePhase 1
    Registry statusCompleted

  • Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)

    NCT02320604 · start 2018-03-22

    Registered record
    Registry ID
    NCT02320604
    Conditions
    Morbid Obesity
    Interventions
    Administration of study drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-22
    Completion
    2018-11-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorbid Obesity
    InterventionAdministration of study drug
    PhasePhase 4
    Registry statusCompleted

  • An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM

    NCT04004078 · start 2018-03-01

    Registered record
    Registry ID
    NCT04004078
    Conditions
    Invasive Fungal Infection
    Interventions
    other antifungal agents,breathing machine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2021-05-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    Interventionother antifungal agents,breathing machine
    PhaseNot recorded
    Registry statusCompleted

  • Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

    NCT02656797 · start 2018-01-30

    Registered record
    Registry ID
    NCT02656797
    Conditions
    Leishmaniasis
    Interventions
    Topical Amphotericin-B 0.4% liposomal gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-30
    Completion
    2021-10-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis
    InterventionTopical Amphotericin-B 0.4% liposomal gel
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

    NCT02971007 · start 2016-11

    Registered record
    Registry ID
    NCT02971007
    Conditions
    Vulvovaginitis; Yeast Infection; Yeast Infection Vaginal; Candidiasis, Vulvovaginal
    Interventions
    Oral Encochleated Amphotericin B (CAMB); Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11
    Completion
    2017-05
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginitis; Yeast Infection; Yeast Infection Vaginal; Candidiasis, Vulvovaginal
    InterventionOral Encochleated Amphotericin B (CAMB); Fluconazole
    PhasePhase 2
    Registry statusCompleted

  • CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

    NCT02629419 · start 2016-09-27

    Registered record
    Registry ID
    NCT02629419
    Conditions
    Candidiasis, Chronic Mucocutaneous
    Interventions
    Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-09-27
    Completion
    2022-08-06
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Chronic Mucocutaneous
    InterventionAmphotericin B
    PhasePhase 2
    Registry statusCompleted

  • Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis

    NCT01566552 · start 2014-06

    Registered record
    Registry ID
    NCT01566552
    Conditions
    Visceral Leishmaniasis
    Interventions
    AMBISOME
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-06
    Completion
    2017-12
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionAMBISOME
    PhasePhase 4
    Registry statusUnknown

  • Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?

    NCT01740947 · start 2013-01

    Registered record
    Registry ID
    NCT01740947
    Conditions
    Colorectal Cancer
    Interventions
    Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2017-03
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSelective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
    PhasePhase 4
    Registry statusTerminated

  • An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

    NCT01652859 · start 2012-02

    Registered record
    Registry ID
    NCT01652859
    Conditions
    Normal Healthy Subjects
    Interventions
    Liposomal Amphotericin B; AmBisome
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2012-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNormal Healthy Subjects
    InterventionLiposomal Amphotericin B; AmBisome
    PhasePhase 1
    Registry statusCompleted